


# 2020 ACC/AHA Guidelines for Aortic Regurgitation



|   |  |  |
|---|--|--|
| <p><b>Class 1</b> Procedure is recommended</p> <p><b>Class 2a</b> Reasonable to perform procedure</p> <p><b>Class 2b</b> Procedure may be reasonable</p> <p><b>Harm</b> In patients with isolated severe AR who have indications for SAVR and are candidates for surgery, TAVI should not be performed.</p> | <p><b>Stage A:</b> At risk of AR<br/> <b>Stage B:</b> Progressive AR<br/> <b>Stage C:</b> Asymptomatic severe AR<br/> <b>Stage D:</b> Symptomatic AR</p> | <p><b>RVol:</b> Regurgitation volume<br/> <b>RF:</b> Regurgitation fraction<br/> <b>ERO:</b> Effective regurgitation orifice<br/> <b>LVEF:</b> LV ejection fraction<br/> <b>LVESD:</b> LV end systolic dimension<br/> <b>LVESD:</b> LV end diastolic dimension</p> |
|---|--|--|

 : Changes from 2014 AHA/ACC Guidelines for Aortic Regurgitation; see back side of page for details.

## Summary of changes from 2014 ACC/AHA Guidelines for Aortic Regurgitation

| Recommendations   | 2014        | 2020           | Changes in 2020   |
|---|-------------|----------------|---|
| Asymptomatic patients with chronic severe AR and LV systolic dysfunction (LVEF <50%) (Stage C2)   | Class 1, B  | Class 1, B-NR  | Updated LVEF ≤55%   |
| Asymptomatic patients with severe AR with normal LV systolic function (LVEF ≥50%) but with severe LV dilation (LVESD >50 mm, stage C2)  | Class 2a, B | Class 2a, B-NR | LVEF ≥55%, LVESD > 25mm/m <sup>2</sup>  |
| Asymptomatic patients with severe AR and normal LV systolic function at rest (LVEF ≥50%, Stage C1) but with progressive severe LV dilatation (LVESD >65 mm) if surgical risk is low | Class 2b, C | Class 2b, B-NR | LV systolic function at rest (LVEF >55%; Stage C1), progressive decline in LVEF to low-normal range (LVEF 55% to 60%) |
| In patients with isolated severe AR who have indications for SAVR and are candidates for surgery, TAVI should not be performed  |             | Class 3, B-NR  | New category added  |

### Reference:

- Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Journal of the American College of Cardiology* (2021)Feb 2;77(4):e25-197.
- Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology* (2014)Jun10;63(22):e57-185.

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2021 Edwards Lifesciences Corporation. All rights reserved. PP--US-3840 v2.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com

